Dataset
The CADISP 2015 dataset contains summary-level data.
Publications
Genome-Wide Association Analysis of Young-Onset Stroke Identifies a Locus on Chromosome 10q25 Near HABP2.
Cheng Y-C, et al.
Stroke. 2016 Feb;47(2):307-16. doi: 10.1161/STROKEAHA.115.011328.
PMID:26732560
Download list of CADISP publications
Phenotypes
- all ischemic stroke
- TOAST cardio-aortic embolism
- TOAST large artery atherosclerosis
- TOAST small artery occlusion
- TOAST other determined
- TOAST other undetermined
Subjects
| Cases | Controls | Ancestry |
|---|---|---|
| 555 | 9,259 | European |
Case selection criteria were as follows:
- Only individuals of European ancestry, aged <18 years by the time of enrollment, are included.
- CAD subjects: Typical radiological aspect of dissection in a cervical artery (carotid, vertebral)
- CAD subject exclusion criteria:
- Purely intracranial dissection
- Iatrogenic dissection after an endovascular procedure
- Monogenic disorder known to cause CAD (e.g., vascular Ehlers–Danlos syndrome)
- Ischemic stroke subjects: Recent ischemic stroke; No sign of CAD on ultrasound and angiography (MR or CT or conventional), performed <7 days after the stroke.
- Ischemic stroke subject exclusion criteria:
- Possible IS with normal cerebral imaging CAD cannot be ruled out (e.g., persistent arterial occlusion without mural hematoma)
- Endovascular or surgical procedure on coronary, cervical, or cerebral arteries <48 h
- Cardiopathies with a very high embolic risk
- Arterial vasospasm after subarachnoid hemorrhage
- Auto-immune disease possibly explaining IS
- Monogenic disease explaining IS
Project
Cervical Artery Dissection and Ischemic Stroke Patients (CADISP) Learn more >
An organized multinational European network, Cervical Artery Dissection and Ischemic Stroke Patients (CADISP) aims at increasing knowledge of the pathophysiological mechanisms of this disease in a large group of patients. This network is aiming to perform a de novo genetic association analysis using both a genome-wide and a candidate gene approach. For this purpose, DNA from approximately 1100 patients with CAD, and 2000 healthy controls is being collected. In addition, detailed clinical, laboratory, diagnostic, therapeutic, and outcome data are being collected from all participants applying predefined criteria and definitions in a standardized way.